TAIPEI, April 25, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Laboratorios Saval ("Saval"), a Chilean-based pharmaceutical company operating in Central and South America, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery. S

SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for limertinib as the first-line treatment f

India’s top drug advisory board is poised to implement a significant overhaul of over-the-counter (OTC) medication sales, aiming to limit the availability of certain drugs to prevent misuse and ensure patient safety. The proposed framework restricts OTC sales to 27 medications, including common antipyretics and painkillers, with specific dosage and quantity limitations.    This initiative marks a pivotal shift in India’s approach to OTC drug regulation, aligning with global standards observed in

President Donald Trump is reviving a controversial proposal to align U.S. prescription drug prices with those in other developed nations, a move that could slash domestic pharmaceutical spending by an estimated $85 billion over seven years. This initiative, known as the “Most Favored Nations” rule, aims to tie Medicare drug payments to the lower prices paid abroad.    The pharmaceutical industry is sounding alarms, labeling the proposal as an “existential threat” that could stifle innovation and

Europe’s pharmaceutical sector is facing a critical juncture as AstraZeneca CEO Pascal Soriot warns of the continent’s declining position in global pharmaceutical innovation. Soriot emphasizes that without significant policy reforms and increased investment, Europe risks losing out on substantial investments, including AstraZeneca’s recent $3.5 billion commitment to the U.S.    Soriot highlights that Europe allocates a significantly lower percentage of its GDP to innovative medicines compared to

A recent investigation has uncovered a disturbing link between a Chinese prison and the U.S. fentanyl epidemic, which claims approximately 100,000 American lives each year.  This revelation has intensified scrutiny on China’s role in the opioid crisis and raised questions about international efforts to curb the flow of this deadly drug.   In a landmark case, nine individuals were convicted in China for smuggling fentanyl into the United States. This joint operation between Chinese and American a

Two of the world’s top pharma executives are sounding the alarm: Europe must act swiftly or face a sharp decline in its role in the global pharmaceutical industry. Novartis CEO Vas Narasimhan and Sanofi CEO Paul Hudson are pressing the EU to rethink its approach to drug pricing as global tariffs and supply chain concerns escalate.   They warn that Europe’s share in global pharmaceutical R&D has dropped to less than 25%, a stark contrast to past decades. The current pricing environment, they argu

The United States and China are facing a critical juncture in their efforts to combat the fentanyl crisis, as escalating trade tensions threaten to derail ongoing negotiations. With over 100,000 overdose deaths in the U.S. in 2022 alone, two-thirds involving fentanyl or similar synthetic drugs, the urgency for effective collaboration has never been higher.    Recent discussions between the two nations have been strained. The U.S. has accused China of insufficient action against the production an

Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricleHeart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug

MIAMI, April 25, 2025 /PRNewswire/ -- Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned neurosurgeon Dr. Neil A. Martin as its Chief Medical Officer (CMO). In this pivotal role, Dr. Martin will lead the advancement of the company's groundbreaking, engine-free, nonlinear, flexible micro-robotic system, poised to transform the treatment landscape for Glioblastoma Multiforme (GBM). Continue Reading "Glioblastoma remains the most treat